Collaboration - December 5, 2014
Nanovector, Affibody to Collaborate
Norway’s Nordic Nanovector ASA and Sweden’s Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant, the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary […]
Clinical Trials - November 10, 2014
New Myeloma Drug Study
Genmab A/S (OMX: GEN) announced that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. is planning an additional Phase III study of daratumumab in frontline multiple myeloma. The study will compare daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTD) to bortezomib, […]
